NAD+ became a central longevity molecule because every cell spends it. For severe depletion (post-COVID fatigue, chronic illness, alcohol recovery, high training loads), IV and injectable NAD+ often improve energy, sleep, and clarity faster than oral precursors. For healthy people taking NMN/NR as "longevity insurance," the case is slower and quieter — precursors raise NAD+ pools, but human lifespan-extension evidence is thin. The practical case is strongest where depletion is likely: metabolic support during rapid GLP-1 fat loss and acute recovery after illness or overtraining.
What Is NAD+ and Why It Matters
NAD+ is better understood as cellular currency — a finite resource four systems compete for.
| System | What it does | NAD+ cost |
|---|---|---|
| Energy production | Carries electrons through mitochondria to make ATP | Constant, ongoing |
| DNA repair | PARP enzymes consume NAD+ to fix DNA damage | Spikes during stress |
| Stress response | Sirtuins regulate adaptation/longevity genes | Activity-dependent |
| Inflammation | CD38 on immune cells breaks down NAD+ for signaling | Accelerates with age |
When the pool is full, all four run smoothly; when depleted (chronic stress, poor sleep, illness, aging), the system rations — fatigue, slow recovery, poor stress tolerance, lingering inflammation.
Why NAD+ Declines With Age
By age 60, most people have lost 50–80% of baseline NAD+.
| Tissue | Decline | Age range |
|---|---|---|
| Plasma NAD+ | ~80% | 20–87 years |
| Skeletal muscle (NAMPT) | ~35% | 20–70 years |
| Liver NAD+ | ~30% | >60 vs <45 years |
| Adipose tissue | 40–50% | Adult aging |
The CD38 / senescent-cell loop is the primary driver: senescent cells accumulate and leak inflammatory signals → macrophages produce 200–300% more CD38 (which breaks down NAD+) → the drain exceeds production → sirtuins (the inflammation brakes) go offline without NAD+ → more inflammation → more destruction. Other drains: chronic DNA damage (PARP overactivation), chronic inflammation, alcohol, viral illness, and sleep disruption. Diet (niacin- and tryptophan-rich foods, trace-NMN foods) supports maintenance but can't restore depleted levels.
Benefits: What the Research Shows
Energy/mitochondria: restored NAD+ raises ATP capacity and mitochondrial efficiency; subjective energy reports inconsistent (Elhassan 2019). Cardiovascular: chronic NR supplementation reduced systolic BP 5–10 mmHg in older adults and improved vascular function (Martens 2018) — one of the more consistent findings. Metabolic: NMN supplementation improved insulin sensitivity in prediabetic women (Yoshino 2021) — small, needs replication. Cognitive: the NADPARK study showed oral NR raises NAD+ in human brain tissue (MRS), with some Parkinson's improvements. Sleep/circadian: NAD+ oscillates over 24 h via NAMPT; chronic depletion flattens it. Inflammation: NR reduced IL-6 and TNF-α in older adults.
| Timeframe | What you might notice |
|---|---|
| Days 1–7 | Subtle energy improvement, especially with IV or injectable NAD+ |
| Weeks 1–4 | Sleep quality changes, brain fog lifting |
| Weeks 4–8 | Sustained energy, better exercise recovery |
| Months 2–3+ | Cumulative metabolic and resilience benefits |
Long COVID: The Clinical Proof Point
SARS-CoV-2 leaves a persistent NAD+-economy collapse — acute infection activates PARP, upregulates CD38, and diverts the kynurenine pathway, causing sharp depletion. Once NAD+ falls below threshold, the system can't self-recover (inflammation brakes fail, mitochondrial biogenesis stalls, the daily rhythm flattens) — resembling accelerated aging compressed into months. A pilot trial (n=36) of NAD+ patches + low-dose naltrexone showed a 52% responder rate; Jiang 2022 showed NAD+/NMN restored mitochondrial respiration after SARS-CoV-2 suppressed NAMPT/NMNAT.
Oral Precursors vs Injectable NAD+
No head-to-head human trial compares the oral precursors: NMN converts to NAD+ in one step, while NR takes an extra step but has the larger body of published trials, and both raise NAD+ levels. IV: Grant 2019 showed no plasma rise until >2 h (rapid tissue uptake), peaking +398% at 6 h — essentially a slow-release delivery of nicotinamide/metabolites; clinic-only. IM and SC: formal pharmacokinetic data are very limited, and SC injections tend to sting more.
Evidence Assessment
Well-established (human RCTs): precursors raise blood NAD+; NR improves BP in older adults; oral precursors are well tolerated in trials; NR raises brain NAD+ (NADPARK). Emerging: NMN insulin sensitivity; NAD+ + LDN 52% Long COVID responder rate; improved muscle function; anti-inflammatory effects. Mechanistically sound (unproven in humans): redox support for GLP-1 fat oxidation; CD38 inhibitors (animal only); healthspan extension (mouse). Unknown: multi-year safety (max trial ~12 weeks), whether blood reflects tissue NAD+, optimal precursor, long-term cancer risk.
Safety and Contraindications
Oral NMN/NR: excellent safety profile in trials (mild GI upset at higher doses). IV: rate-dependent nausea, cramping, chest tightness, and lightheadedness — patients with a cardiac history should get medical clearance first. Injected SC or IM, NAD+ is acidic and stings on contact; seek care if pain lasts more than 30 minutes, redness spreads, hives, swelling, or breathing trouble appear, lumps persist beyond 7 days, or fever develops. Absolute contraindications: active cancer (NAD+ supports cellular metabolism and may fuel tumor cells), pregnancy/breastfeeding, severe hepatic or renal impairment. Caution: cancer history (consult oncologist), arrhythmias, diabetes on metformin, chemotherapy. The cancer concern is theoretical with no signal in human data, but anyone with active cancer should not supplement.